On January 12, a number of pharmaceutical stocks were reduced, involving WuXi AppTec, China Pharmaceutical, Yixintang and so on

On January 12, a number of pharmaceutical stocks were reduced, including WuXi AppTec, China Pharmaceutical, Yixintang, Renfu Pharmaceutical, etc
.
The author has briefly sorted
out this.
China Pharmaceutical China Pharmaceutical was reduced by 1.
773 million shares by Shanghai Stock Connect, and the new holding volume was 29.
6007 million shares, accounting for 1.
98%
of the total share capital of the company's A shares.
As of the close on January 12, China National Pharmaceutical closed at 15.
19 yuan, down 1.
04%, with a turnover rate of 3.
05%, a volume of 455,500 lots and a turnover of 696 million yuan
.
In terms of capital flow data on January 12, the net outflow of main funds was 51.
8361 million yuan, accounting for 7.
44% of the total turnover, the net outflow of floating funds was 17.
1507 million yuan, accounting for 2.
46% of the total turnover, and the net inflow of retail funds was 68.
9869 million yuan, accounting for 9.
91% of
the total turnover.
According to the data, China National Pharmaceutical is a listed company controlled by General Technology Group and has now become an asset integration platform
for pharmaceuticals and medical devices under the group.
Renfu Pharmaceutical Renfu Pharmaceutical was reduced by Shanghai Stock Connect by 244,700 shares, which has been reduced by Shanghai Stock Connect for 3 consecutive days, a total of 995,600 shares, and the new holding volume is 26,860,300 shares, accounting for 1.
65%
of the total share capital of the company's A shares.
As of the close on January 12, Renfu Pharmaceutical closed at 25.
42 yuan, down 0.
39%, with a turnover rate of 0.
71%, a volume of 103,900 lots and a turnover of 266 million yuan
.
In terms of capital flow data on January 12, the net outflow of main funds was 7.
1621 million yuan, accounting for 2.
69% of the total turnover, the net outflow of floating funds was 607,200 yuan, accounting for 0.
23% of the total turnover, and the net inflow of retail funds was 7.
7693 million yuan, accounting for 2.
92% of
the total turnover.
According to the data, Renfu Pharmaceutical is mainly engaged in the research and development, production and sales
of drugs.
Yixintang Yixintang was reduced by 768,300 shares by Shenzhen Stock Connect, and the new holding amount was 44,547,600 shares, accounting for 7.
47%
of the total share capital of the company's A shares.
As of the close on January 12, Yixintang closed at 32.
95 yuan, down 0.
96%, with a turnover rate of 0.
9%, a volume of 35,700 lots and a turnover of 118 million yuan
.
In terms of capital flow data on January 12, the net inflow of main funds was 977,300 yuan, accounting for 0.
83% of the total turnover, the net outflow of floating funds was 10.
747 million yuan, accounting for 9.
14% of the total turnover, and the net inflow of retail funds was 9.
7696 million yuan, accounting for 8.
31% of
the total turnover.
According to the data, Yixintang's main business is pharmaceutical retail chain and pharmaceutical wholesale business, and the company's main business scope includes the operation and sales
of traditional Chinese medicine, western medicine and medical devices.
Tibet Pharmaceutical On January 12, Tibet Pharmaceutical was reduced by 96,500 shares by Shanghai Stock Connect, and the new holding amount was 2,107,600 shares, accounting for 0.
85%
of the total share capital of the company's A shares.
As of the close on January 12, Tibet Pharmaceutical closed at 36.
29 yuan, up 0.
19%, with a turnover rate of 0.
55%, a volume of 13,700 lots, and a turnover of 49.
9635 million yuan
.
In terms of capital flow data on January 12, the net outflow of main funds was 1.
9554 million yuan, accounting for 3.
91% of the total turnover, the net outflow of floating funds was 548,400 yuan, accounting for 1.
1% of the total turnover, and the net inflow of retail funds was 2.
5038 million yuan, accounting for 5.
01% of
the total turnover.
According to the data, Tibet Pharmaceutical mainly produces and sells capsules, biological agents, granules, coating agents, etc
.
WuXi AppTec WuXi AppTec announced that its shareholders controlled by the actual controller of the company and shareholders who signed a concerted action agreement with the actual controller, shareholders controlled by the actual controller of the company, shareholders who signed a concerted action agreement with the actual controller, and shareholders who signed a proxy letter with the actual controller of the company reduced their holdings by a total of 66,596,700 shares between December 19, 2022 and January 11, 2023, accounting for 2.
2499% of the company's current total share capital, and the stock price increased by 13.
25% during the change period , as of January 11, it closed at 89.
56 yuan
.
As of the close on January 12, WuXi AppTec closed at 90.
92 yuan, up 1.
52%, with a turnover rate of 0.
78%, a volume of 200,500 lots, and a turnover of 1.
831 billion yuan
.
The stock has changed in shareholders' holdings in the past half year, with a total net reduction of 26.
5207 million shares
.
According to the data, WuXi AppTec is a drug R&D service platform, the company's R&D services cover chemical drug R&D and production, cell and gene therapy R&D and production, medical device testing and other fields
.
*ST Bicon *ST Bicon announced on January 12 that the company received a notice from Li Zongsong, the company's second largest shareholder, on January 12, 2023, and Li Zongsong passively reduced his holdings of 2.
0599 million shares of the company on January 11, accounting for 0.
13%
of the company's total share capital.
After the forced liquidation, Li Zongsong held 142 million shares of the company, accounting for 9.
33%
of the company's total share capital.
The cumulative number of pledged shares of Li Zongsong is 142 million shares, accounting for 99.
48% of the number of shares held by Li Zongsong and 9.
28%
of the total share capital of the company.
Among them, the number of shares pledged to Bohai Securities was 14.
2978 million shares, accounting for 0.
93%
of the company's total share capital.
As of the close on January 12, *ST Bicon closed at 7.
64 yuan, up 0.
92%, with a turnover rate of 1.
39%, a volume of 213,500 lots and a turnover of 166 million yuan
.
In terms of capital flow data on January 12, the net outflow of main funds was 3.
1887 million yuan, accounting for 1.
92% of the total turnover, the net outflow of floating funds was 4.
905 million yuan, accounting for 2.
96% of the total turnover, and the net inflow of retail funds was 8.
0937 million yuan, accounting for 4.
89% of
the total turnover.
According to the data, *ST Bicon currently focuses on new energy, pharmaceuticals and pharmaceutical intermediates
.
KEMEI DIAGNOSTICS KEMEI DIAGNOSTICS ANNOUNCED THAT ITS SHAREHOLDERS, SHANGHAI PEIXI INVESTMENT MANAGEMENT PARTNERSHIP (LIMITED PARTNERSHIP) AND HJ CAPITAL 2 LIMITED, REDUCED THEIR HOLDINGS BY A TOTAL OF 4.
210 MILLION SHARES BETWEEN JANUARY 4, 2023 AND JANUARY 11, 2023, ACCOUNTING OF 1.
0499%
OF THE COMPANY'S CURRENT TOTAL SHARE CAPITAL.
As of the close on January 12, Kemei Diagnostics closed at 11.
46 yuan, down 0.
35%, with a turnover rate of 1.
91%, a volume of 52,100 lots, and a turnover of 60.
1315 million yuan
.
According to industry statistics, the stock has changed in shareholders' holdings in the past six months, with a total net reduction of 21.
9679 million shares
.
According to the data, Kemei Diagnostics is an enterprise
mainly engaged in the research and development, production and sales of clinical immunochemiluminescence diagnostic detection reagents and instruments.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.